Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma

Phase 2

Completed

Conditions: Metastatic Melanoma

Interventions: Biological: Melanoma Reactive TIL
Drug: Cyclophosphamide
Biological: IL-2
Drug: Fludarabine
Radiation: 1200 total body irradiation (TBI)

First Posted Date: 2006-04-12

Last Posted Date: 2012-10-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 26

Registration Number: NCT00314106

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

Phase 2

Completed

Conditions: Acute Lymphocytic Leukemia
MDS
Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Lymphoma
Refractory Anemia
Myelodysplastic Syndromes
Chronic Myelogenous Leukemia
Myelofibrosis
Prolymphocytic Leukemia

Interventions: Biological: filgrastim
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Procedure: umbilical cord blood transplantation
Radiation: total-body irradiation

First Posted Date: 2006-04-03

Last Posted Date: 2020-09-10

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 213

Registration Number: NCT00309842

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission

Phase 1

Completed

Conditions: Congenital Amegakaryocytic Thrombocytopenia
Diamond-blackfan Anemia
Fanconi Anemia
Leukemia
Severe Congenital Neutropenia
Thrombocytopenia

First Posted Date: 2006-03-22

Last Posted Date: 2012-11-12

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 40

Registration Number: NCT00305708

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Myelodysplastic Syndromes
Myeloproliferative Disorders

Interventions: Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: Fludarabine
Drug: mycophenolate mofetil
Procedure: umbilical cord blood transplantation
Radiation: total body irradiation
Drug: Sirolimus

First Posted Date: 2006-03-22

Last Posted Date: 2020-11-19

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 295

Registration Number: NCT00305682

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Phase 2

Terminated

Conditions: Kidney Cancer
Leukemia
Lymphoma
Multiple Myeloma
Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine
Drug: mycophenolate mofetil
Procedure: stem cell transplantation
Radiation: total body irradiation
Drug: filgrastim

First Posted Date: 2006-03-17

Last Posted Date: 2020-05-12

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 342

Registration Number: NCT00303719

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Phase 1

Completed

Conditions: Acute Myelogenous Leukemia

Interventions: Biological: aldesleukin
Biological: natural killer cells
Drug: fludarabine phosphate
Biological: Thymoglobulin
Procedure: allogeneic hematopoietic stem cell transplantation
Radiation: total body irradiation
Drug: cyclophosphamide
Drug: Cyclosporin A

First Posted Date: 2006-03-17

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 50

Registration Number: NCT00303667

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Biological: sargramostim
Drug: busulfan
Drug: etoposide
Drug: fludarabine phosphate
Drug: prednisone
Drug: tacrolimus
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: umbilical cord blood transplantation

First Posted Date: 2006-03-17

Last Posted Date: 2013-08-14

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 5

Registration Number: NCT00304018

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Phase 2

Terminated

Conditions: Recurrent Melanoma
Stage IV Melanoma

Interventions: Drug: cyclophosphamide
Drug: fludarabine phosphate
Biological: therapeutic autologous lymphocytes
Procedure: in vitro-treated peripheral blood stem cell transplantation
Biological: gp100 antigen
Biological: MART-1 antigen
Biological: incomplete Freund's adjuvant
Biological: filgrastim
Biological: aldesleukin

First Posted Date: 2006-03-17

Last Posted Date: 2013-06-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 58

Registration Number: NCT00303836

Locations: 🇺🇸
National Cancer Institute Surgery Branch, Bethesda, Maryland, United States

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Phase 2

Withdrawn

Conditions: Anemia
Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2006-03-13

Last Posted Date: 2012-10-02

Lead Sponsor: University of California, San Francisco

Registration Number: NCT00301912

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer

Not Applicable

Terminated

Conditions: Lymphoma
Leukemia

First Posted Date: 2006-03-13

Last Posted Date: 2013-07-15

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 8

Registration Number: NCT00301860

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy